Compare Natco Pharma with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA WYETH LTD NATCO PHARMA/
WYETH LTD
 
P/E (TTM) x 15.4 27.7 55.5% View Chart
P/BV x 3.0 5.3 56.5% View Chart
Dividend Yield % 1.5 1.3 115.7%  

Financials

 NATCO PHARMA   WYETH LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
WYETH LTD
Mar-13
NATCO PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,0801,044 103.4%   
Low Rs671818 82.1%   
Sales per share (Unadj.) Rs592.1298.6 198.3%  
Earnings per share (Unadj.) Rs188.457.2 329.1%  
Cash flow per share (Unadj.) Rs206.358.4 353.3%  
Dividends per share (Unadj.) Rs8.2517.00 48.5%  
Dividend yield (eoy) %0.91.8 51.6%  
Book value per share (Unadj.) Rs833.6249.5 334.1%  
Shares outstanding (eoy) m36.9022.72 162.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.1 47.4%   
Avg P/E ratio x4.616.3 28.6%  
P/CF ratio (eoy) x4.215.9 26.6%  
Price / Book Value ratio x1.13.7 28.1%  
Dividend payout %4.429.7 14.7%   
Avg Mkt Cap Rs m32,31121,157 152.7%   
No. of employees `0004.80.5 981.9%   
Total wages/salary Rs m3,256400 814.0%   
Avg. sales/employee Rs Th4,522.513,787.4 32.8%   
Avg. wages/employee Rs Th674.0813.0 82.9%   
Avg. net profit/employee Rs Th1,439.02,643.3 54.4%   
INCOME DATA
Net Sales Rs m21,8486,783 322.1%  
Other income Rs m404353 114.6%   
Total revenues Rs m22,2527,136 311.8%   
Gross profit Rs m9,2841,617 574.0%  
Depreciation Rs m66227 2,488.7%   
Interest Rs m1546 2,800.0%   
Profit before tax Rs m8,8721,938 457.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,920632 303.7%   
Profit after tax Rs m6,9521,301 534.6%  
Gross profit margin %42.523.8 178.2%  
Effective tax rate %21.632.6 66.3%   
Net profit margin %31.819.2 166.0%  
BALANCE SHEET DATA
Current assets Rs m21,3076,984 305.1%   
Current liabilities Rs m5,9202,056 288.0%   
Net working cap to sales %70.472.6 96.9%  
Current ratio x3.63.4 106.0%  
Inventory Days Days7399 73.8%  
Debtors Days Days10724 444.9%  
Net fixed assets Rs m14,986244 6,134.3%   
Share capital Rs m369227 162.4%   
"Free" reserves Rs m30,3535,441 557.9%   
Net worth Rs m30,7605,668 542.7%   
Long term debt Rs m025 0.0%   
Total assets Rs m37,1517,901 470.2%  
Interest coverage x58.6353.3 16.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 68.5%   
Return on assets %19.116.5 115.7%  
Return on equity %22.622.9 98.5%  
Return on capital %29.334.0 86.2%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m10,32215 67,906.3%   
Fx outflow Rs m2,9782,677 111.3%   
Net fx Rs m7,343-2,662 -275.9%   
CASH FLOW
From Operations Rs m4,636923 502.2%  
From Investments Rs m-11,155317 -3,520.0%  
From Financial Activity Rs m6,509-481 -1,353.2%  
Net Cashflow Rs m-18759 -2.4%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 51.1 2.9%  
Indian inst/Mut Fund % 7.8 11.3 69.4%  
FIIs % 16.6 7.2 231.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 30.4 85.5%  
Shareholders   25,395 21,978 115.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Gains 300 Points; Hero MotoCorp & Maruti Suzuki Top Gainers(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Signs of easing trade tension between the US and China provided some respite to investors globally.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 15, 2019 01:59 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS